{"transactions":[{"id":685581,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-17T21:01:12.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":1772,"price":59.1415,"value":104798.738,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.98 to $59.52 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001814876-26-000027","document":"wk-form4_1787000470.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000027/wk-form4_1787000470.xml","form_type":"4"}},{"id":685580,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-17T21:01:12.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":9230,"price":58.5864,"value":540752.472,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.99 to $58.98 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1772,"source":{"system":"sec-edgar","filing":"0001814876-26-000027","document":"wk-form4_1787000470.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000027/wk-form4_1787000470.xml","form_type":"4"}},{"id":693127,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class E Ordinary Shares","published_at":"2026-08-07T21:24:13.000Z","date":"2026-08-07","kind":"gift","planned":false,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote (2)"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No Class E Ordinary Shares of RPH (\"Class E Shares\") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"No Class E Ordinary Shares of RPH (\"Class E Shares\") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"No Class E Ordinary Shares of RPH (\"Class E Shares\") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"No Class E Ordinary Shares of RPH (\"Class E Shares\") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"No Class E Ordinary Shares of RPH (\"Class E Shares\") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."}],"balance_after":1788777,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001814876-26-000025","document":"wk-form4_1786137851.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000025/wk-form4_1786137851.xml","form_type":"4"}},{"id":693126,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-07T21:24:13.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":11002,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":11002,"source":{"system":"sec-edgar","filing":"0001814876-26-000025","document":"wk-form4_1786137851.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000025/wk-form4_1786137851.xml","form_type":"4"}},{"id":760279,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-28T20:48:21.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":64399,"price":53.9778,"value":3476116.3422,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $54.63 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001814876-26-000022","document":"wk-form4_1780001297.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000022/wk-form4_1780001297.xml","form_type":"4"}},{"id":786926,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-08T21:14:41.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":24263,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":64399,"source":{"system":"sec-edgar","filing":"0001814876-26-000020","document":"wk-form4_1778274879.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000020/wk-form4_1778274879.xml","form_type":"4"}},{"id":796911,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-04-30T21:54:06.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":49.7784,"value":93334.5,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.46 to $50.18 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40136,"source":{"system":"sec-edgar","filing":"0001814876-26-000018","document":"wk-form4_1777586044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000018/wk-form4_1777586044.xml","form_type":"4"}},{"id":796910,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-04-30T21:54:06.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":32916,"price":49.7784,"value":1638505.8144,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.46 to $50.18 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001814876-26-000018","document":"wk-form4_1777586044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000018/wk-form4_1777586044.xml","form_type":"4"}},{"id":819737,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-04-02T21:58:57.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":32916,"price":48.3318,"value":1590889.5288,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.07 to $48.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":32916,"source":{"system":"sec-edgar","filing":"0001814876-26-000016","document":"wk-form4_1775167135.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000016/wk-form4_1775167135.xml","form_type":"4"}},{"id":819736,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-04-02T21:58:57.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":48.3318,"value":90622.125,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.07 to $48.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":42011,"source":{"system":"sec-edgar","filing":"0001814876-26-000016","document":"wk-form4_1775167135.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000016/wk-form4_1775167135.xml","form_type":"4"}},{"id":828254,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-03-25T21:05:22.000Z","date":"2026-03-23","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":45.5287,"value":85366.3125,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.30 to $45.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43886,"source":{"system":"sec-edgar","filing":"0001814876-26-000014","document":"wk-form4_1774472720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000014/wk-form4_1774472720.xml","form_type":"4"}},{"id":828253,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-03-25T21:05:22.000Z","date":"2026-03-23","kind":"sale","planned":true,"acquired":false,"shares":32916,"price":45.5287,"value":1498622.6892,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.30 to $45.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":65832,"source":{"system":"sec-edgar","filing":"0001814876-26-000014","document":"wk-form4_1774472720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000014/wk-form4_1774472720.xml","form_type":"4"}},{"id":861742,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-03-04T22:11:47.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":583,"price":47.0143,"value":27409.3369,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.94 to $47.16 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":45761,"source":{"system":"sec-edgar","filing":"0001814876-26-000012","document":"wk-form4_1772662304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000012/wk-form4_1772662304.xml","form_type":"4"}},{"id":861741,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-03-04T22:11:47.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1292,"price":46.6747,"value":60303.7124,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.93 to $46.92 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46344,"source":{"system":"sec-edgar","filing":"0001814876-26-000012","document":"wk-form4_1772662304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000012/wk-form4_1772662304.xml","form_type":"4"}},{"id":861740,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-03-04T22:11:47.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":10429,"price":47.0145,"value":490314.2205,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.94 to $47.16 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":98748,"source":{"system":"sec-edgar","filing":"0001814876-26-000012","document":"wk-form4_1772662304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000012/wk-form4_1772662304.xml","form_type":"4"}},{"id":861739,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-03-04T22:11:47.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":22487,"price":46.6717,"value":1049506.5179,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.93 to $46.92 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":109177,"source":{"system":"sec-edgar","filing":"0001814876-26-000012","document":"wk-form4_1772662304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000012/wk-form4_1772662304.xml","form_type":"4"}},{"id":882088,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-25T21:08:28.000Z","date":"2026-02-23","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":45.3165,"value":84968.4375,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.60 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":47636,"source":{"system":"sec-edgar","filing":"0001814876-26-000010","document":"wk-form4_1772053705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000010/wk-form4_1772053705.xml","form_type":"4"}},{"id":882087,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-25T21:08:28.000Z","date":"2026-02-23","kind":"sale","planned":true,"acquired":false,"shares":32916,"price":45.3165,"value":1491637.914,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.60 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":131664,"source":{"system":"sec-edgar","filing":"0001814876-26-000010","document":"wk-form4_1772053705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000010/wk-form4_1772053705.xml","form_type":"4"}},{"id":905321,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-13T21:03:15.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":26626,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":49511,"source":{"system":"sec-edgar","filing":"0001814876-26-000008","document":"wk-form4_1771016592.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000008/wk-form4_1771016592.xml","form_type":"4"}},{"id":919507,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-04T22:07:40.000Z","date":"2026-02-04","kind":"sale","planned":true,"acquired":false,"shares":1087,"price":43.2928,"value":47059.2736,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.11 to $43.51 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":22885,"source":{"system":"sec-edgar","filing":"0001814876-26-000006","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000006/wk-form4_1770242855.xml","form_type":"4"}},{"id":919506,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-04T22:07:40.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":6195,"price":42.8431,"value":265413.0045,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.35 to $43.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":23972,"source":{"system":"sec-edgar","filing":"0001814876-26-000006","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000006/wk-form4_1770242855.xml","form_type":"4"}},{"id":919505,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-04T22:07:40.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":5843,"price":42.0839,"value":245896.2277,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.45 to $42.37 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":30167,"source":{"system":"sec-edgar","filing":"0001814876-26-000006","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000006/wk-form4_1770242855.xml","form_type":"4"}},{"id":919504,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-04T22:07:40.000Z","date":"2026-02-04","kind":"sale","planned":true,"acquired":false,"shares":19076,"price":43.2928,"value":825853.4528,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.11 to $43.51 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":164580,"source":{"system":"sec-edgar","filing":"0001814876-26-000006","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000006/wk-form4_1770242855.xml","form_type":"4"}},{"id":919503,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-04T22:07:40.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":108759,"price":42.8432,"value":4659583.5888,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.35 to $43.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":183656,"source":{"system":"sec-edgar","filing":"0001814876-26-000006","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000006/wk-form4_1770242855.xml","form_type":"4"}},{"id":919502,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-04T22:07:40.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":102581,"price":42.0839,"value":4317008.5459,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.45 to $42.37 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":292415,"source":{"system":"sec-edgar","filing":"0001814876-26-000006","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000006/wk-form4_1770242855.xml","form_type":"4"}},{"id":932408,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-23T21:48:33.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":3750,"price":39.3484,"value":147556.5,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.86 to $39.66 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":36010,"source":{"system":"sec-edgar","filing":"0001814876-26-000004","document":"wk-form4_1769204910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000004/wk-form4_1769204910.xml","form_type":"4"}},{"id":932407,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-23T21:48:33.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":65832,"price":39.3484,"value":2590383.8688,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.86 to $39.66 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":394996,"source":{"system":"sec-edgar","filing":"0001814876-26-000004","document":"wk-form4_1769204910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000004/wk-form4_1769204910.xml","form_type":"4"}},{"id":946902,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-06T21:18:43.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":3750,"price":38.4157,"value":144058.875,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.29 to $38.64 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":39760,"source":{"system":"sec-edgar","filing":"0001814876-26-000002","document":"wk-form4_1767734318.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000002/wk-form4_1767734318.xml","form_type":"4"}},{"id":946901,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-06T21:18:43.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":65832,"price":38.4157,"value":2528982.3624,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.29 to $38.64 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":460828,"source":{"system":"sec-edgar","filing":"0001814876-26-000002","document":"wk-form4_1767734318.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487626000002/wk-form4_1767734318.xml","form_type":"4"}},{"id":965121,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-17T22:39:45.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":3750,"price":38.3601,"value":143850.375,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $38.48 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43510,"source":{"system":"sec-edgar","filing":"0001814876-25-000011","document":"wk-form4_1766011182.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000011/wk-form4_1766011182.xml","form_type":"4"}},{"id":965120,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-17T22:39:45.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":65832,"price":38.3601,"value":2525322.1032,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $38.48 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":526660,"source":{"system":"sec-edgar","filing":"0001814876-25-000011","document":"wk-form4_1766011182.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000011/wk-form4_1766011182.xml","form_type":"4"}},{"id":981669,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-03T22:11:18.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":3750,"price":39.866,"value":149497.5,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.64 to $40.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":47260,"source":{"system":"sec-edgar","filing":"0001814876-25-000009","document":"wk-form4_1764799875.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000009/wk-form4_1764799875.xml","form_type":"4"}},{"id":981668,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-03T22:11:18.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":65832,"price":39.866,"value":2624458.512,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.64 to $40.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":592492,"source":{"system":"sec-edgar","filing":"0001814876-25-000009","document":"wk-form4_1764799875.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000009/wk-form4_1764799875.xml","form_type":"4"}},{"id":987221,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-26T22:01:45.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":624,"price":37.9595,"value":23686.728,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.32 to $38.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":51010,"source":{"system":"sec-edgar","filing":"0001814876-25-000007","document":"wk-form4_1764194502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000007/wk-form4_1764194502.xml","form_type":"4"}},{"id":987220,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-26T22:01:45.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":3126,"price":38.6699,"value":120882.1074,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.33 to $38.96 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":51634,"source":{"system":"sec-edgar","filing":"0001814876-25-000007","document":"wk-form4_1764194502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000007/wk-form4_1764194502.xml","form_type":"4"}},{"id":987219,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-26T22:01:45.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":10686,"price":37.9604,"value":405644.8344,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.32 to $38.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":658324,"source":{"system":"sec-edgar","filing":"0001814876-25-000007","document":"wk-form4_1764194502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000007/wk-form4_1764194502.xml","form_type":"4"}},{"id":987218,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-26T22:01:45.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":55146,"price":38.6663,"value":2132291.7798,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.33 to $38.96 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":669010,"source":{"system":"sec-edgar","filing":"0001814876-25-000007","document":"wk-form4_1764194502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000007/wk-form4_1764194502.xml","form_type":"4"}},{"id":993911,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-19T21:53:33.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":3750,"price":39.304,"value":147390.0,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.97 to $39.50 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":54760,"source":{"system":"sec-edgar","filing":"0001814876-25-000005","document":"wk-form4_1763589210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000005/wk-form4_1763589210.xml","form_type":"4"}},{"id":993910,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-19T21:53:33.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":65844,"price":39.3041,"value":2587939.1604,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.97 to $39.50 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":724156,"source":{"system":"sec-edgar","filing":"0001814876-25-000005","document":"wk-form4_1763589210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000005/wk-form4_1763589210.xml","form_type":"4"}},{"id":1004925,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-07T21:18:55.000Z","date":"2025-11-05","kind":"grant","planned":false,"acquired":true,"shares":6168,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":58510,"source":{"system":"sec-edgar","filing":"0001814876-25-000003","document":"wk-form4_1762550332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000181487625000003/wk-form4_1762550332.xml","form_type":"4"}},{"id":1071417,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2025-08-08T20:58:17.000Z","date":"2025-08-08","kind":"gift","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC ICAI, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":43350,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001802768-25-000104","document":"wk-form4_1754686694.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000104/wk-form4_1754686694.xml","form_type":"4"}},{"id":1071416,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-08-08T20:58:17.000Z","date":"2025-08-06","kind":"grant","planned":false,"acquired":true,"shares":3696,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":52342,"source":{"system":"sec-edgar","filing":"0001802768-25-000104","document":"wk-form4_1754686694.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000104/wk-form4_1754686694.xml","form_type":"4"}},{"id":1140526,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class E Ordinary Shares","published_at":"2025-05-20T20:52:53.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":1807277,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote (1)(2)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares (\"Class E Shares\") of Royalty Pharma Holdings Ltd (\"RPH\") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as many be amended from time to time, the \"Purchase Agreement\") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."}],"balance_after":1807277,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":1807277},"source":{"system":"sec-edgar","filing":"0001802768-25-000067","document":"wk-form4_1747774366.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000067/wk-form4_1747774366.xml","form_type":"4"}},{"id":1153818,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2025-05-09T21:10:41.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":48646,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"TPC RP EPA1 LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":48646,"source":{"system":"sec-edgar","filing":"0001802768-25-000033","document":"wk-form4_1746825035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000033/wk-form4_1746825035.xml","form_type":"4"}},{"id":1436062,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"ICAI Interests","published_at":"2024-08-12T23:20:32.000Z","date":"2024-08-12","kind":"gift","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC ICAI, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"No ICAI Interests or limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. ICAI Interests represent a grant of an equivalent number of limited partnership interest in RPI US LP (\"RPI US LP Interest\"). Each RPI US LP Interest may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person made a charitable donation of ICAI Interests. No Class A Ordinary Shares, RPI US LP Interests or ICAI Interests were sold."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents ICAI Interests. Each ICAI Interests represents a grant of an equivalent number of RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents ICAI Interests. Each ICAI Interests represents a grant of an equivalent number of RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":44350,"derivative":{"underlying":"LP interests in RPI US Partners 2019, LP","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001802768-24-000051","document":"wk-form4_1723504825.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276824000051/wk-form4_1723504825.xml","form_type":"4"}},{"id":1810006,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2023-08-11T21:00:35.000Z","date":"2023-08-10","kind":"sale","planned":true,"acquired":false,"shares":37500,"price":30.7491,"value":1153091.25,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.55 to $31.07 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":790000,"source":{"system":"sec-edgar","filing":"0001209191-23-045463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123045463/doc4.xml","form_type":"4"}},{"id":1810005,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2023-08-11T21:00:35.000Z","date":"2023-08-09","kind":"sale","planned":true,"acquired":false,"shares":37500,"price":30.7183,"value":1151936.25,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.41 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":827500,"source":{"system":"sec-edgar","filing":"0001209191-23-045463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123045463/doc4.xml","form_type":"4"}},{"id":1813003,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"ICAI Interests","published_at":"2023-08-08T21:37:41.000Z","date":"2023-08-08","kind":"gift","planned":false,"acquired":false,"shares":1650,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC ICAI, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"No ICAI Interests or limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. ICAI Interests represent a grant of an equivalent number of limited partnership interest in RPI US LP (\"RPI US LP Interest\"). Each RPI US LP Interest may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person made a charitable donation of ICAI Interests. No Class A Ordinary Shares, RPI US LP Interests or ICAI Interests were sold."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents ICAI Interests. Each ICAI Interests represents a grant of an equivalent number of RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents ICAI Interests. Each ICAI Interests represents a grant of an equivalent number of RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":46350,"derivative":{"underlying":"Limited Partnership interests in RPI US Partners 2019, LP","underlying_shares":1650},"source":{"system":"sec-edgar","filing":"0001209191-23-045064","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123045064/doc4.xml","form_type":"4"}},{"id":1829607,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2023-07-14T22:09:10.000Z","date":"2023-07-13","kind":"sale","planned":true,"acquired":false,"shares":37500,"price":30.9322,"value":1159957.5,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.77 to $31.44 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":865000,"source":{"system":"sec-edgar","filing":"0001209191-23-042297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123042297/doc4.xml","form_type":"4"}},{"id":1829606,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2023-07-14T22:09:10.000Z","date":"2023-07-12","kind":"sale","planned":true,"acquired":false,"shares":37500,"price":31.0735,"value":1165256.25,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.79 to $31.43 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":902500,"source":{"system":"sec-edgar","filing":"0001209191-23-042297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123042297/doc4.xml","form_type":"4"}},{"id":2120119,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2022-11-10T22:04:19.000Z","date":"2022-11-08","kind":"sale","acquired":false,"shares":24500,"price":43.4699,"value":1065012.55,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.85 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.85 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":940000,"source":{"system":"sec-edgar","filing":"0001209191-22-056420","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919122056420/doc4.xml","form_type":"4"}},{"id":2124517,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2022-11-04T23:16:28.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":5500,"price":43.0629,"value":236845.95,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.17 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.17 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":964500,"source":{"system":"sec-edgar","filing":"0001209191-22-055873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919122055873/doc4.xml","form_type":"4"}},{"id":2195984,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2022-08-03T23:12:30.000Z","date":"2022-08-01","kind":"sale","acquired":false,"shares":30000,"price":43.1909,"value":1295727.0,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.47 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.47 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":970000,"source":{"system":"sec-edgar","filing":"0000899243-22-027643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000089924322027643/doc4.xml","form_type":"4"}},{"id":2718830,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2021-05-12T01:05:28.000Z","date":"2021-05-07","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 3,251,930 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":22945,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000950103-21-007077","document":"dp150857_4-coyne.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321007077/dp150857_4-coyne.xml","form_type":"4"}},{"id":2718829,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2021-05-12T01:05:28.000Z","date":"2021-05-07","kind":"exercise","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC RP 2021, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 3,251,930 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0000950103-21-007077","document":"dp150857_4-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321007077/dp150857_4-coyne.xml","form_type":"4"}},{"id":2806484,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2021-03-06T00:04:34.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":1456,"price":46.83,"value":68184.48,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"balance_after":200000,"source":{"system":"sec-edgar","filing":"0000950103-21-003634","document":"dp147400_4-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321003634/dp147400_4-coyne.xml","form_type":"4"}},{"id":2806483,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2021-03-06T00:04:34.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":11001,"price":45.8557,"value":504458.5557,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.57 to $46.41 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":201456,"source":{"system":"sec-edgar","filing":"0000950103-21-003634","document":"dp147400_4-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321003634/dp147400_4-coyne.xml","form_type":"4"}},{"id":2806482,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2021-03-06T00:04:34.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":57723,"price":45.0854,"value":2602464.5442,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.50 to $45.46 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":212457,"source":{"system":"sec-edgar","filing":"0000950103-21-003634","document":"dp147400_4-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321003634/dp147400_4-coyne.xml","form_type":"4"}},{"id":2806481,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2021-03-06T00:04:34.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":29820,"price":43.707,"value":1303342.74,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.47 to $44.46 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":270180,"source":{"system":"sec-edgar","filing":"0000950103-21-003634","document":"dp147400_4-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321003634/dp147400_4-coyne.xml","form_type":"4"}},{"id":2809136,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2021-03-05T00:00:51.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":5022,"price":47.8752,"value":240429.2544,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.60 to $48.05 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0000950103-21-003568","document":"dp147385_4-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321003568/dp147385_4-coyne.xml","form_type":"4"}},{"id":2809135,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2021-03-05T00:00:51.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":94978,"price":46.8915,"value":4453660.887,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.54 to $47.50 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":305022,"source":{"system":"sec-edgar","filing":"0000950103-21-003568","document":"dp147385_4-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321003568/dp147385_4-coyne.xml","form_type":"4"}},{"id":2921272,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2021-01-06T02:53:53.000Z","date":"2020-12-31","kind":"exercise","acquired":false,"shares":30023,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes RPI US LP Interests convertible into 3,251,928 Class A Ordinary Shares that are subject to an agreement by and between the reporting person and RP Management, LLC under which the reporting person has agreed to retain and not sell such interests before February 2025. This restriction is waivable under certain circumstances."}],"balance_after":376468,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":300230},"source":{"system":"sec-edgar","filing":"0000950103-21-000110","document":"dp143910_4-coyne.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321000110/dp143910_4-coyne.xml","form_type":"4"}},{"id":2921271,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2021-01-06T02:53:53.000Z","date":"2020-12-31","kind":"exercise","acquired":false,"shares":9977,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes RPI US LP Interests convertible into 7,780 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":778,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":99770},"source":{"system":"sec-edgar","filing":"0000950103-21-000110","document":"dp143910_4-coyne.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321000110/dp143910_4-coyne.xml","form_type":"4"}},{"id":2921270,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2021-01-06T02:53:53.000Z","date":"2020-12-31","kind":"exercise","acquired":true,"shares":300230,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."}],"balance_after":400000,"source":{"system":"sec-edgar","filing":"0000950103-21-000110","document":"dp143910_4-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321000110/dp143910_4-coyne.xml","form_type":"4"}},{"id":2921269,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2021-01-06T02:53:53.000Z","date":"2020-12-31","kind":"exercise","acquired":true,"shares":99770,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."}],"balance_after":99770,"source":{"system":"sec-edgar","filing":"0000950103-21-000110","document":"dp143910_4-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321000110/dp143910_4-coyne.xml","form_type":"4"}},{"id":2921268,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"LP interests in RPI International Holdings 2019, LP","published_at":"2021-01-06T02:51:18.000Z","date":"2020-06-18","kind":"exercise","acquired":false,"shares":2417,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse's IRA"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such distribution for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such distribution for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes RPI Intl. LP Interests convertible into 1,880 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"These LP Interests were omitted from the Reporting Person's original Form 4 for transactions on June 18, 2020"}],"balance_after":188,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":24170},"source":{"system":"sec-edgar","filing":"0000950103-21-000109","document":"dp143924_4a-coyne.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321000109/dp143924_4a-coyne.xml","form_type":"4/A","original_submission_date":"2020-06-23"}},{"id":2921267,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"LP interests in RPI International Holdings 2019, LP","published_at":"2021-01-06T02:51:18.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":2605,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse's IRA"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such distribution for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such distribution for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes RPI Intl. LP Interests convertible into 1,880 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"These LP Interests were omitted from the Reporting Person's original Form 4 for transactions on June 18, 2020"}],"balance_after":2605,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":26050},"source":{"system":"sec-edgar","filing":"0000950103-21-000109","document":"dp143924_4a-coyne.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321000109/dp143924_4a-coyne.xml","form_type":"4/A","original_submission_date":"2020-06-23"}},{"id":2921266,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2021-01-06T02:51:18.000Z","date":"2020-06-18","kind":"exercise","acquired":true,"shares":24170,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse's IRA"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."}],"balance_after":24170,"source":{"system":"sec-edgar","filing":"0000950103-21-000109","document":"dp143924_4a-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321000109/dp143924_4a-coyne.xml","form_type":"4/A","original_submission_date":"2020-06-23"}},{"id":3102121,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"LP interests in RPI International Holdings 2019, LP","published_at":"2020-06-24T01:21:28.000Z","date":"2020-06-18","kind":"exercise","acquired":false,"shares":2327,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By IRA"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP Interests\"). Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such distribution for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP Interests\"). Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such distribution for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Includes RPI Intl. LP Interests convertible into 1,810 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":181,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":23270},"source":{"system":"sec-edgar","filing":"0000950103-20-012254","document":"dp130858_4-coyne.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012254/dp130858_4-coyne.xml","form_type":"4"}},{"id":3102120,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"ICAI Interests","published_at":"2020-06-24T01:21:28.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"These ICAI Interests represent a grant of up to 48,000 limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales pursuant to a formula from 0% at $28.00 per share to 100% at $32.30 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"These ICAI Interests represent a grant of up to 48,000 limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales pursuant to a formula from 0% at $28.00 per share to 100% at $32.30 per share."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":48000,"derivative":{"exercise_price":0,"underlying":"Limited Partnership interests in RPI US Partners 2019, LP","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0000950103-20-012254","document":"dp130858_4-coyne.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012254/dp130858_4-coyne.xml","form_type":"4"}},{"id":3102119,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"ICAI Interests","published_at":"2020-06-24T01:21:28.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":305000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"These ICAI Interests represent a grant of up to 305,000 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"These ICAI Interests represent a grant of up to 305,000 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":305000,"derivative":{"exercise_price":0,"underlying":"Limited Partnership interests in RPI US Partners 2019, LP","underlying_shares":305000},"source":{"system":"sec-edgar","filing":"0000950103-20-012254","document":"dp130858_4-coyne.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012254/dp130858_4-coyne.xml","form_type":"4"}},{"id":3102118,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"LP interests in RPI International Holdings 2019, LP","published_at":"2020-06-24T01:21:28.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":2508,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By IRA"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP Interests\"). Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such distribution for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP Interests\"). Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such distribution for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Includes RPI Intl. LP Interests convertible into 1,810 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":2508,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":25080},"source":{"system":"sec-edgar","filing":"0000950103-20-012254","document":"dp130858_4-coyne.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012254/dp130858_4-coyne.xml","form_type":"4"}},{"id":3102117,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2020-06-24T01:21:28.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":406491,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes RPI US LP Interests convertible into 3,251,928 Class A Ordinary Shares that are subject to an agreement by and between the reporting person and RP Management, LLC under which the reporting person has agreed to retain and not sell such interests before February 2025. This restriction is waivable under certain circumstances."}],"balance_after":406491,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":4064910},"source":{"system":"sec-edgar","filing":"0000950103-20-012254","document":"dp130858_4-coyne.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012254/dp130858_4-coyne.xml","form_type":"4"}},{"id":3102116,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2020-06-24T01:21:28.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":10755,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By TPC RP, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes RPI US LP Interests convertible into 7,780 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":10755,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":107550},"source":{"system":"sec-edgar","filing":"0000950103-20-012254","document":"dp130858_4-coyne.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012254/dp130858_4-coyne.xml","form_type":"4"}},{"id":3102115,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2020-06-24T01:21:28.000Z","date":"2020-06-18","kind":"exercise","acquired":true,"shares":23270,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By IRA"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."}],"balance_after":23270,"source":{"system":"sec-edgar","filing":"0000950103-20-012254","document":"dp130858_4-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012254/dp130858_4-coyne.xml","form_type":"4"}},{"id":3102114,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2020-06-24T01:21:28.000Z","date":"2020-06-18","kind":"purchase","acquired":true,"shares":1450,"price":28,"value":40600.0,"ownership":{"direct":false,"nature":"By Spouse"},"balance_after":1450,"source":{"system":"sec-edgar","filing":"0000950103-20-012254","document":"dp130858_4-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012254/dp130858_4-coyne.xml","form_type":"4"}},{"id":3102113,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":22893,"kind":"person","name":"Coyne Terrance P.","position":1,"cik":"0001814876","reported_name":"Coyne Terrance P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Class A Ordinary Shares","published_at":"2020-06-24T01:21:28.000Z","date":"2020-06-18","kind":"purchase","acquired":true,"shares":1500,"price":28,"value":42000.0,"ownership":{"direct":true},"balance_after":1500,"source":{"system":"sec-edgar","filing":"0000950103-20-012254","document":"dp130858_4-coyne.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012254/dp130858_4-coyne.xml","form_type":"4"}}]}